While the use of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA199) as biomarkers for COAD diagnosis and prognosis prediction is prevalent in clinical settings, their suboptimal performance in this regard has been well-documented [4]. This evidence concerns the gene CEACAM5 and colon adenocarcinoma.